Floriano-Sánchez E, Torres-Salazar JJ, Cárdenas-Rodríguez N, Castro-Marín M, Zapata-Villalba MA, Flores Terrazas JE

Language: Spanish
References: 8
Page: 137-140
PDF size: 532.29 Kb.

ABSTRACT

Background: Recent reports have placed prostate cancer in third place worldwide; in Mexico it is the principal cause of death by cancer in men after lung cancer and more than 70% of cases present in advanced stages. Several genetic markers for prostate cancer are being studied but there are very few studies on cyclooxygenase-2 in the literature. For this reason the present study evaluates whether or not there is any alteration of cyclooxygenase-2 levels in prostate cancer and benign prostatic hyperplasia.
Methods: From a total of 81 samples, 39 corresponded to benign prostatic hyperplasia tissue and 42 corresponded to prostate cancer tissue. Conditions were standardized in order to immunohistochemically detect the presence of cyclooxygenase-2.
Results: The percentages of the area that was immunoreactive to cyclooxygenase-2 in stroma were 7.41% in prostate cancer and 12.11% in benign prostatic hyperplasia. These percentages in the gland were 5.12% in prostate cancer and 14.76% in benign prostatic hyperplasia.
Conclusions: Cyclooxygenase-2 expression levels in prostate cancer tissue were significantly lower than those obtained in benign prostatic hyperplasia tissue, suggesting that this gene could be used as a marker in early development of prostate cancer.

REFERENCES

1. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997;94(7):3336-3340.

2. Chu J, Lloyd FL, Trifan OC, Knapp B. Potential involment of the Cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003;2(1):1-7.

3. Samaka RM, Abdou AG, Abd El-Wahed MM. Cyclooxygenase-2 expression in chronic gastritis and gastric carcinoma, correlation with pronostic parameters. J Egypt Natl Canc Inst 2006;18(4):363-374.

4. 4. Wang W, Bergh A, Damber JE. Cyclooxygenase-2 Expression Correlates with Local Chronic Inflammation and Tumor Neovascularization in Human Prostate Cancer. Clin Cancer Res 2005;11(9):3250-3256.

5. Rikio Yoshimura R, Sano H. Expression of cyclooxygenase-2 in prostate carcinoma. Am Can Soc 2000;89:589-596.

6. Zha S, Gage WR, Sauvageot J. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61(24):8617-23.

7. Spinella F, Rosano L. Inhibition of Cyclooxygenase-1 and -2: expression by Targeting the endothelin A receptor in Human Ovarian Carcinoma Cells. Clin Cancer Res 2004;10:4670–4679.

8. Madaan S, Abel PD. Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU International 2000; 86:736-741.